Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 3.3% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 3.3% during mid-day trading on Wednesday . The stock traded as low as $23.07 and last traded at $23.08. Approximately 17,679 shares changed hands during trading, a decline of 91% from the average daily volume of 205,885 shares. The stock had previously closed at $23.86.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Raymond James upped their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, November 8th. Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Wedbush reduced their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.43.

Dianthus Therapeutics Trading Down 0.1 %

The stock has a fifty day simple moving average of $26.82 and a 200 day simple moving average of $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently modified their holdings of the company. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $112,000. The Manufacturers Life Insurance Company purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth $236,000. Fred Alger Management LLC increased its holdings in shares of Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $265,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.